Suppr超能文献

甲状腺癌患者的甲状腺相关眼病:5例病例报告

Thyroid-associated orbitopathy in patients with thyroid carcinoma: A case report of 5 cases.

作者信息

Yu Peng, Liu Siyue, Zhou Xinrong, Huang Teng, Li Yaling, Wang Hong, Yuan Gang

机构信息

Department of Internal Medicine Molecular Diagnostic Laboratory, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei, China.

出版信息

Medicine (Baltimore). 2017 Nov;96(47):e8768. doi: 10.1097/MD.0000000000008768.

Abstract

RATIONALE

Thyroid-associated orbitopathy (TAO) is most often seen in patients with autoimmune thyroid disease. Data about TAO occurred in patients with thyroid carcinoma are rare. We give a report of 5 patients to present the clinical characteristics, treatment, and prognosis of this type of case.

PATIENT CONCERNS

Five thyroid carcinoma patients presented with orbitopathy. Among them, two patients (patient 1 and 4) were hyperthyroid and TSH receptor antibody (TRAb) positive, two patients (patient 3 and 5) were euthyroid and displayed slightly elevated TRAb titres, one patient (patient 2) was euthyroid and TRAb negative.

DIAGNOSES

They were diagnosed as thyroid carcinoma and TAO.

INTERVENTIONS

Patient 1 underwent total thyroidectomy, intravenous glucocorticoids (GCs) therapy, orbital decompression surgery and oral GCs therapy. Patient 2 and 3 only received total thyroidectomy. Patient 4 received sub-total thyroidectomy and oral GCs therapy. patient 5 didn't received thyroidectomy and underwent intravenous GCs therapy for 2 courses.

OUTCOMES

Patient 1,2,3 showed an improvement of TAO at the final follow-up. Patient 4,5 showed no improvement of TAO at the final follow-up.

LESSONS

When TAO present in patients with thyroid nodules, the possibility of thyroid carcinoma should be considered, and the nature of these nodules should be carefully evaluated. In some patients with thyroid carcinoma and TAO, the remission of TAO can be seen post total thyroidectomy. But for other patients, besides thyroidectomy, an adequate dose and course of intravenous GCs treatment and even ocular surgery are also needed.

摘要

理论依据

甲状腺相关眼病(TAO)最常见于自身免疫性甲状腺疾病患者。关于甲状腺癌患者发生TAO的数据很少。我们报告5例患者,以呈现此类病例的临床特征、治疗及预后情况。

患者情况

5例甲状腺癌患者出现眼眶病变。其中,2例患者(患者1和4)甲状腺功能亢进且促甲状腺素受体抗体(TRAb)阳性,2例患者(患者3和5)甲状腺功能正常且TRAb滴度略有升高,1例患者(患者2)甲状腺功能正常且TRAb阴性。

诊断

他们被诊断为甲状腺癌和TAO。

干预措施

患者1接受了甲状腺全切除术、静脉注射糖皮质激素(GCs)治疗、眼眶减压手术及口服GCs治疗。患者2和3仅接受了甲状腺全切除术。患者4接受了甲状腺次全切除术及口服GCs治疗。患者5未接受甲状腺切除术,接受了2个疗程的静脉注射GCs治疗。

结果

患者1、2、3在最后一次随访时TAO有所改善。患者4、5在最后一次随访时TAO未改善。

经验教训

当TAO出现在甲状腺结节患者中时,应考虑甲状腺癌的可能性,并仔细评估这些结节的性质。在一些甲状腺癌合并TAO的患者中,甲状腺全切除术后TAO可缓解。但对于其他患者,除甲状腺切除外,还需要足够剂量和疗程的静脉注射GCs治疗,甚至眼部手术。

相似文献

1
Thyroid-associated orbitopathy in patients with thyroid carcinoma: A case report of 5 cases.
Medicine (Baltimore). 2017 Nov;96(47):e8768. doi: 10.1097/MD.0000000000008768.
2
Development of Thyroid-Associated Ophthalmopathy in Patients Who Underwent Total Thyroidectomy.
Yonsei Med J. 2015 Sep;56(5):1389-94. doi: 10.3349/ymj.2015.56.5.1389.
3
Graves' ophthalmopathy after total thyroidectomy for papillary carcinoma.
Ann Endocrinol (Paris). 2011 Feb;72(1):42-4. doi: 10.1016/j.ando.2010.11.001. Epub 2010 Dec 31.
4
Severe unilateral orbitopathy in a patient with Hashimoto's thyroiditis - a case report.
BMC Ophthalmol. 2019 Jan 8;19(1):9. doi: 10.1186/s12886-018-1018-5.
6
Long-term multidisciplinary follow-up of unilateral thyroid-associated orbitopathy.
Eur J Intern Med. 2008 Nov;19(7):531-6. doi: 10.1016/j.ejim.2008.01.013. Epub 2008 Mar 18.
7
Papillary thyroid carcinoma with thyroid-associated orbitopathy in a euthyroid state.
Ophthalmic Plast Reconstr Surg. 2007 May-Jun;23(3):187-91. doi: 10.1097/IOP.0b013e31803e1755.
9
Pathological Findings of the Thyroid Tissue in a Patient with Euthyroid Graves' Disease.
Intern Med. 2015;54(22):2881-4. doi: 10.2169/internalmedicine.54.3346. Epub 2015 Nov 15.
10
Severe thyroid-associated orbitopathy in Hashimoto's thyroiditis. Report of 2 cases.
Endocr J. 2011;58(5):343-8. doi: 10.1507/endocrj.k11e-019. Epub 2011 Mar 17.

引用本文的文献

1
Graves' orbitopathy development in thyroid cancer patients: a 16-year nationwide cohort study in South Korea.
Eye (Lond). 2024 Oct;38(15):2955-2959. doi: 10.1038/s41433-024-03197-9. Epub 2024 Jun 28.

本文引用的文献

1
MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials.
Eur J Endocrinol. 2017 Feb;176(2):R101-R109. doi: 10.1530/EJE-16-0552. Epub 2016 Oct 19.
3
Current Insights into the Pathogenesis of Graves' Ophthalmopathy.
Horm Metab Res. 2015 Sep;47(10):773-8. doi: 10.1055/s-0035-1555762. Epub 2015 Sep 11.
4
Orbital decompression in thyroid eye disease.
ISRN Ophthalmol. 2012 Nov 12;2012:739236. doi: 10.5402/2012/739236. eCollection 2012.
5
Intraocular pressure lowering effect of orbital decompression is related to increased venous outflow in Graves orbitopathy.
Curr Eye Res. 2014 Jul;39(7):666-72. doi: 10.3109/02713683.2013.867355. Epub 2014 Feb 6.
6
Cancer risk in patients with Graves' disease: a nationwide cohort study.
Thyroid. 2013 Jul;23(7):879-84. doi: 10.1089/thy.2012.0568.
7
Choroidal and orbital metastases from thyroid cancer.
Thyroid. 2013 May;23(5):543-51. doi: 10.1089/thy.2012.0021. Epub 2013 Apr 18.
9
Clinical features of thyroid-associated ophthalmopathy in clinically euthyroid Korean patients.
Eye (Lond). 2012 Sep;26(9):1263-9. doi: 10.1038/eye.2012.132. Epub 2012 Jun 29.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验